Methods and compositions for diagnosing neoplastic disease
Methods and compositions for determining whether a subject at least has a neoplastic disease are provided. In practicing the subject methods, a sample from a subject is assayed for a soluble filamin analyte, such as a filamin A analyte, to determine whether the subject at least has the neoplastic disease. Also provided are kits, systems, and devices for practicing the subject methods.
1 . A method of diagnosing whether a subject has a neoplastic disease, said method comprising:
assaying an extracellular sample from said subject for a soluble filamin analyte to diagnose whether said subject has said neoplastic disease.
2 . The method according to claim 1 , wherein said soluble filamin analyte is a soluble filamin A analyte.
3 . The method according to claim 1 , wherein said extracellular sample is qualititatively assayed for said soluble filamin analyte.
4 . The method according to claim 1 , wherein said extracellular sample is quantitatively assayed for said soluble filiman analyte.
5 . The method according to claim 1 , wherein said assaying employs a filamin analyte affinity reagent.
6 . The method according to claim 5 , wherein said filamin analyte affinity reagent is an antibody reagent.
7 . The method according to claim 5 , wherein said assaying employs two distinct filamin analyte affinity reagents.
8 . The method according to claim 1 , wherein said method is a method of monitoring progression of said neoplastic disease of said subject.
9 . The method according to claim 1 , wherein said extracellular sample is a blood sample.
10 . The method according to claim 1 , wherein said neoplastic disease is a carcinoma.
11 . The method according to claim 1 , wherein said carcinoma is breast cancer.
12 . The method according to claim 1 , wherein said carcinoma is ovarian cancer.
13 . A method of treating a subject having a neoplastic disease, said method comprising:
(a) diagnosing whether said subject suffers from a neoplastic disease by assaying an extracellular sample from said subject for a soluble filamin analyte; and
(b) treating said subject based on results from said diagnosing step (a).
14 . The method according to claim 13 , wherein said soluble filamin analyte is a soluble filamin A analyte.
15 . A kit for use in diagnosing whether a subject has a neoplastic disease, comprising:
reagents for assaying a sample for a soluble filamin analyte; and
a reference.
16 . The kit according to claim 15 , wherein said soluble filamin analyte is a soluble filamin A analyte.
17 . The kit according to claim 15 , wherein said reagents comprise at least one filamin analyte specific affinity reagent.
18 . The kit according to claim 17 , wherein said filamin analyte affinity reagent is an antibody reagent.
19 . The kit according to claim 17 , wherein said affinity reagent comprises a detectable label.
20 . The kit according to claim 17 , wherein said at least one filamin analyte specific affinity reagent is immobilized on a surface of a solid support.
21 . The kit according to claim 15 , wherein said kit further comprises a sample obtainment element.
22 . A system for use in diagnosing whether a subject has a neoplastic disease, comprising:
reagents for assaying a sample for a soluble filamin analyte; and
a reference.
23 . The system according to claim 22 , wherein said soluble filamin analyte is a soluble filamin A analyte.
24 . The system according to claim 22 , wherein said reagents comprise at least one filamin analyte specific affinity reagent.
25 . The system according to claim 22 , wherein said filamin analyte affinity reagent is an antibody reagent.
26 . The system according to claim 24 , wherein said affinity reagent comprises a detectable label.
27 . The system according to claim 24 , wherein said at least one filamin analyte specific affinity reagent is immobilized on a surface of a solid support.
28 . The system according to claim 22 , wherein said system further comprises a sample obtainment element.
29 . A device for use in diagnosing whether a subject suffers from a neoplastic disease, said device comprising:
a soluble filamin analyte specific affinity reagent immobilized on a surface of a solid support.
30 . The device according to claim 29 , wherein said soluble filamin analyte is a soluble filamin A analyte.
31 . The device according to claim 29 , wherein said soluble filamin analyte specific affinity reagent comprises an antibody or binding fragment thereof.
32 . The device according to claim 29 , wherein said antibody is a monoclonal antibody.
33 . An antibody that specifically binds to a soluble form of a filamin analyte.
34 . The antibody of claim 33 , wherein the soluble form of the filamin analyte is a soluble form of a filamin A analyte.
35 . The antibody of claim 33 , wherein the antibody is a polyclonal antibody.
36 . The antibody of claim 33 , wherein the antibody is a monoclonal antibody.
37 . A cell that secretes an antibody according to claim 36 .
38 . The cell according to claim 38 , wherein said cell is a hybridoma cell.